Publikationen in Zusammenarbeit mit Forschern von Fondazione IRCCS Istituto Nazionale dei Tumori (10)

2022

  1. A First-in-Human, Phase I, Multicenter, Open-Label, Dose-Escalation Study of PCA062: An Antibody-Drug Conjugate Targeting P-Cadherin, in Patients With Solid Tumors

    Molecular Cancer Therapeutics, Vol. 21, Núm. 4, pp. 625-634

  2. Phase I/II study of the LAG-3 inhibitor ieramilimab (LAG525) ± anti-PD-1 spartalizumab (PDR001) in patients with advanced malignancies

    Journal for immunotherapy of cancer, Vol. 10, Núm. 2

2021

  1. Corrigendum to ‘Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival’: [Annals of Oncology Volume 32, Issue 8, August 2021, Pages 1015-1024](S0923753421015532)(10.1016/j.annonc.2021.05.353)

    Annals of Oncology

  2. Ribociclib plus fulvestrant for postmenopausal women with hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer in the phase III randomized MONALEESA-3 trial: updated overall survival

    Annals of Oncology, Vol. 32, Núm. 8, pp. 1015-1024

2020

  1. Overall survival with ribociclib plus fulvestrant in advanced breast cancer

    New England Journal of Medicine, Vol. 382, Núm. 6, pp. 514-524

  2. Ribociclib plus fulvestrant for advanced breast cancer: Health-related quality-of-life analyses from the MONALEESA-3 study

    Breast, Vol. 54, pp. 148-154

2018

  1. Phase III randomized study of ribociclib and fulvestrant in hormone receptor-positive, human epidermal growth factor receptor 2-negative advanced breast cancer: MONALEESA-3

    Journal of Clinical Oncology, Vol. 36, Núm. 24, pp. 2465-2472

2011

  1. Relevance of breast cancer hormone receptors and other factors to the efficacy of adjuvant tamoxifen: Patient-level meta-analysis of randomised trials

    The Lancet, Vol. 378, Núm. 9793, pp. 771-784

2010

  1. Overview of the randomized trials of radiotherapy in ductal carcinoma in situ of the breast

    Journal of the National Cancer Institute - Monographs, Vol. 41, pp. 162-177

2001

  1. Cardiac function following combination therapy with paclitaxel and doxorubicin: An analysis of 657 women with advanced breast cancer

    Annals of Oncology, Vol. 12, Núm. 8, pp. 1067-1073